Lisata Therapeutics (NASDAQ:LSTA) Receives Buy Rating from HC Wainwright

Lisata Therapeutics (NASDAQ:LSTA)‘s stock had its “buy” rating reiterated by HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $15.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 420.83% from the company’s previous close.

Lisata Therapeutics Stock Performance

NASDAQ LSTA opened at $2.88 on Thursday. The stock has a market cap of $24.16 million, a P/E ratio of -1.15 and a beta of 1.22. Lisata Therapeutics has a fifty-two week low of $2.05 and a fifty-two week high of $3.83. The stock has a 50 day simple moving average of $2.93 and a two-hundred day simple moving average of $3.09.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.16. During the same period in the previous year, the business posted ($0.65) earnings per share. Sell-side analysts predict that Lisata Therapeutics will post -2.84 earnings per share for the current year.

Hedge Funds Weigh In On Lisata Therapeutics

An institutional investor recently raised its position in Lisata Therapeutics stock. Dimensional Fund Advisors LP raised its position in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 17,336 shares of the company’s stock after acquiring an additional 5,639 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.21% of Lisata Therapeutics worth $60,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.